Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by ...
Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...
To read all of these articles and more, visit centerforbiosimilars.com.
A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...
The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback